Results 111 to 120 of about 17,743 (275)

Supplementary Protocol from Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma [PDF]

, 2023
Kanwal Raghav, Suyu Liu, Michael J. Overman, Anneleis F. Willett, Mark Knafl, Szu‐Chin Fu, Anais Malpica, Seema Prasad, Richard E. Royal, Christopher P. Scally, Paul F. Mansfield, Ignacio I. Wistuba, P. Andrew Futreal, Dipen M. Maru, Luisa M. Solis Soto, Edwin R. Parra, Honglei Chen, Pamela Villalobos, Anuj Verma, Armeen Mahvash, Patrick Hwu, Patricia Cortazar, Edward McKenna, Cindy Yun, Shannon Dervin, Katja Schulze, Walter C. Darbonne, Ajaykumar C. Morani, Scott Kopetz, Keith F. Fournier, Scott E. Woodman, James C. Yao, Gauri R. Varadhachary, Daniel M. Halperin   +33 more
openalex   +1 more source

Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports

Case Reports in Oncology
Introduction: Peritoneal mesothelioma is an extremely rare malignancy of the peritoneum. It has a poor prognosis, and the optimal systemic chemotherapy remains controversial.
Tomonobu Koizumi, Shintaro Kanda, Nodoka Sekiguchi, Takuro Noguchi, Sei-ichiro Eda, Hiroto Kitahara   +5 more
doaj   +1 more source

Mesotelioma Maligno Primário do Peritoneu Associado a Carcinoma de Células Renais. Revisão Concisa [PDF]

, 2010
O Mesotelioma peritoneal maligno é um tumor maligno relacionado frequentemente com exposição prolongada a fibras de amianto, de mau prognóstico, de diagnóstico geralmente tardio, face à pouca expressão clínica na fase inicial da doença.
Baptista, M, Carvalho, A, Damásio, H, Figueiredo, AM, Martins, AR, Murillo, MJ, Murinello, A, Nunes, G   +7 more
core  

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

A Case of Unsuspected Peritoneal Mesothelioma Occurring with Colonic Adenocarcinoma Masquerading as Peritoneal Metastases

Case Reports in Pathology, 2014
We report a case of synchronous primary colonic adenocarcinoma and malignant mesothelioma. A 61-year-old male presented with a six-month history of fatigue and weight loss.
Wei Xie, Linda K. Green, Rishi A. Patel, Syeling Lai   +3 more
doaj   +1 more source

Peritoneal mesothelioma in a woman who has survived for seven years: a case report

Journal of Medical Case Reports, 2011
Introduction Malignant peritoneal mesothelioma is a rare cancer with poor patient survival. Female gender has been identified as a positive prognostic factor.
Pourgholami Mohammad H, Akhter Javed, Pillai Krishna, Morris David L   +3 more
doaj   +1 more source

Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy [PDF]

, 2017
OBJECTIVES: Malignant mesothelioma is closely associated to asbestos exposure. One such exposure may occur through contact with occupationally exposed household members and their belongings.
D'Agostin, Flavia, De Michieli, Paola, Negro, Corrado   +2 more
core   +2 more sources

The application of immunocytochemistry to direct smears in the diagnosis of effusions [PDF]

, 2012
Metastatic malignancy represents a common cause of effusions. Immunocytochemistry (ICC) is useful in confirming malignancy and gaining insight into the site of origin.
Fields, Kristina L., Knoepp, Stewart M., Placido, Jeremiah, Roh, Michael H., Thomas, Dafydd   +4 more
core   +1 more source

GATA3 positive spindle cell neoplasm involving the liver diagnosed as metastatic sarcomatoid chromophobe renal cell carcinoma at autopsy

Histopathology, Volume 87, Issue 6, Page 956-958, December 2025.
Rangsinee Nusapan, Amer Abu Alfa, Agnes Balla, Sharon Mount, John M Kennedy   +4 more
wiley   +1 more source

Anti-CTLA-4 therapy for malignant mesothelioma [PDF]

, 2017
Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1.
Bakker, EY, Guazzelli, A, Krstic-Demonacos, M, Lisanti, MP, Mutti, L, Sotgia, F   +5 more
core   +2 more sources